Drugs for pediatric neurological conditions

Advicenne is a specialty pharmaceutical company focused on developing innovative treatments for rare renal diseases, with a commitment to improving the lives of patients across all age groups. The company has dedicated over a decade to the research and development of its products, which include Sibnayal, a treatment specifically designed for rare renal conditions. Advicenne emphasizes the importance of making groundbreaking therapies accessible to both children and adults, reflecting its dedication to addressing the unique needs of patients suffering from these rare diseases.

In addition to Sibnayal, Advicenne markets other products such as Likozam and Levidcen in France. Likozam, which contains the active substance clobazam, is available in oral suspension forms, while Levidcen, containing levetiracetam, is offered in various dosages as coated granules. Both products are tailored to meet specific patient needs and are marketed exclusively in France. Advicenne's ongoing efforts to achieve regulatory milestones, such as positive FDA opinions for its products, further demonstrate its commitment to advancing treatment options for rare renal diseases.

France

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases.

Advicenne have spent more than 10 years developing products for the treatment of rare renal diseases.

At Advicenne, we are committed to developing and commercializing medicines that are suitable for both children and adults – groundbreaking treatments for rare diseases should be available to patients of all ages.

Advicenne

Company Details